Andreas Wenzel
Novartis
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Andreas Wenzel.
Advances in Experimental Medicine and Biology | 2006
Christian Grimm; Andreas Wenzel; Niyazi Acar; Stephan Keller; M. W. Seeliger; Max Gassmann
Reduced tissue oxygenation stabilizes the alpha-subunit of the transcription factor hypoxia-inducible factor-1 (HIF-1). This leads to the induction of a number of hypoxia responsive genes. One of the best known HIF-1 targets is erythropoietin that exerts neuroprotective effects on ischemia-related injury in the brain. Thus, pre-exposure to low environmental oxygen concentrations might be exploited as a preconditioning procedure to protect tissues against a variety of harmful conditions. We present recent work on neuroprotection of retinal photoreceptors induced by hypoxic preconditioning or by systemically elevated levels of Epo in mouse plasma.
British Journal of Ophthalmology | 2016
Christian Prünte; Franck Fajnkuchen; Sajjad Mahmood; Federico Ricci; Katja Hatz; Jan Studnička; Vladimir Bezlyak; Soumil Parikh; William John Stubbings; Andreas Wenzel; João Figueira
Aims To demonstrate non-inferiority of ranibizumab treat-and-extend (T&E) with/without laser to ranibizumab pro re nata (PRN) for best-corrected visual acuity (BCVA) in patients with diabetic macular oedema (DMO). Methods A 24-month single-masked study with patients randomised 1:1:1 to T&E+laser (n=121), T&E (n=128) or PRN (control; n=123). All patients received monthly injections until BCVA stabilisation. The investigator decided on re-treatment in the PRN and treatment-interval adaptations in the T&E groups based on loss of BCVA stability due to DMO activity. Likewise, laser treatment was at investigators discretion. Collectively, these features reflect a real-life scenario. Endpoints included mean average change in BCVA from baseline to months 1–12 (primary), mean BCVA change from baseline to months 12 and 24, treatment exposure and safety profile. Results Both T&E regimens were non-inferior to PRN based on mean average BCVA change from baseline to months 1–12 (T&E+laser: +5.9 and T&E: +6.1 vs PRN: +6.2 letters; both p<0.0001). Mean BCVA change at month 24 was similar across groups (+8.3, +6.5 and +8.1 letters, respectively). The mean number of injections was 12.4 and 12.8 in the T&E+laser and T&E groups and 10.7 in the PRN group. The T&E regimens showed 46% reduction in the number of clinic visits. Over 70% of patients maintained their BCVA, with treatment intervals of ≥2 months over 24 months. Safety profile was consistent with that described in the product information. Conclusions T&E is a feasible treatment option for patients with DMO, with a potential to reduce treatment burden. Slightly more injections were required versus PRN, likely due to the specifics of the T&E regimen applied here. Trial registration number NCT01171976.
Ophthalmology | 2016
Michael Larsen; Sebastian M. Waldstein; Francesco Boscia; H. Gerding; Jordi Monés; Ramin Tadayoni; Siegfried G. Priglinger; Andreas Wenzel; Elizabeth Barnes; Stefan Pilz; William John Stubbings; Ian Pearce
Ophthalmology | 2016
Ramin Tadayoni; Sebastian M. Waldstein; Francesco Boscia; H. Gerding; Ian Pearce; Siegfried G. Priglinger; Andreas Wenzel; Elizabeth Barnes; Margarita Gekkieva; Stefan Pilz; Jordi Monés
Ophthalmology | 2016
Frank G. Holz; Pravin U. Dugel; Georges Weissgerber; Robin Hamilton; Rufino Silva; Francesco Bandello; Michael Larsen; Andreas Weichselberger; Andreas Wenzel; Anne Schmidt; Dominik Escher; Laura Sararols; Eric H. Souied
Ophthalmology | 2017
Ramin Tadayoni; Sebastian M. Waldstein; Francesco Boscia; H. Gerding; Margarita Gekkieva; Elizabeth Barnes; Ayan Das Gupta; Andreas Wenzel; Ian Pearce
Ophthalmology | 2018
Giovanni Staurenghi; Timothy Y. Y. Lai; Paul Mitchell; Sebastian Wolf; Andreas Wenzel; Jun Li; Amitabha Bhaumik; Philip Hykin
Ophthalmology Retina | 2017
Michael Larsen; Sebastian M. Waldstein; Siegfried G. Priglinger; Philip Hykin; Elizabeth Barnes; Margarita Gekkieva; Ayan Das Gupta; Andreas Wenzel; Jordi Monés
Investigative Ophthalmology & Visual Science | 2016
Chirag Jhaveri; Andreas Wenzel; Andreas Weichselberger
Investigative Ophthalmology & Visual Science | 2015
Jost Hillenkamp; Georg Spital; Andreas Wenzel; Philippe Margaron; Jessica Voegeler